Sign in

CIK 0001841387 · <br>Emerging growth company

Candel Therapeutics, Inc.

Sign in to watch
Ticker
CADL
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
522214851
Phone
617-916-5445
Business address
117 KENDRICK STREET, SUITE 450, NEEDHAM, MA, 02494
  1. 4 Grant or award Director acquired 2,141 shares (grant or award)
  2. 4 Grant or award Chief Financial Officer acquired 5,353 shares (grant or award)
  3. 4 Grant or award Director acquired 5,353 shares (grant or award)
  4. 4 Grant or award Chief Scientific Officer acquired 4,282 shares (grant or award)
  5. 4 Grant or award Director acquired 64,239 shares (grant or award)
  6. 4 Derivatives Options or other derivatives
  7. 4 Derivatives Options or other derivatives
  8. 4 Derivatives Options or other derivatives
  9. 4 Derivatives Options or other derivatives
  10. 4 Derivatives Options or other derivatives
  11. 4 Derivatives Options or other derivatives
  12. 4 Derivatives Options or other derivatives
  13. 4 Derivatives Options or other derivatives
  14. 4 Derivatives Options or other derivatives
  15. 4 Derivatives Options or other derivatives
  16. 3 Insider Initial Statement of Ownership
  17. 4 Planned sale Chief Medical Officer sold 45,316 shares at $8.76 ($396,995)
  18. 4 Planned sale Chief Scientific Officer sold 32,146 shares at $8.76 ($281,673)
  19. 4 Planned sale Chief Executive Officer sold 26,172 shares at an average $8.77 ($229,624)
  20. 4/A Planned sale Chief Technology Officer sold 31,278 shares at $8.82 ($275,947)

Page 3 of 11 · 202 filings